Articles

In this video, Dr Sara Tolaney underscores the positive overall survival outcomes from the monarchE trial, reinforcing the impact of adjuvant abemaciclib plus endocrine therapy in high-risk, hormone receptor (HR)-positive/HER2-negative early breast cancer, while also noting the sustained 5-year benefits observed with ribociclib and nonsteroidal aromatase inhibitors in the NATALEE trial. Read More ›

Sacituzumab Govitecan vs Chemotherapy in Advanced Triple-Negative Breast Cancer: Results From the ASCENT-03 Phase 3 Study

This ASCENT-03 Phase 3 study compared sacituzumab govitecan with chemotherapy in patients with previously untreated advanced TNBC who are ineligible for PD-L1 inhibitors, demonstrating potential efficacy and safety in this challenging population. Read More ›

First Clinical Data of DB-1305/BNT325 (TROP2 ADC) in Pretreated TNBC: Phase 1/2 Efficacy and Safety Insights

This phase 1/2 trial presents the first clinical data on DB-1305/BNT325, a TROP2-targeting antibody–drug conjugate, demonstrating efficacy and safety in patients with pretreated triple-negative breast cancer. Read More ›

Patient-Reported Outcomes in ASCENT-04/KEYNOTE-D19: Sacituzumab Govitecan + Pembrolizumab vs Chemotherapy + Pembrolizumab in PD-L1–positive Metastatic Triple-Negative Breast Cancer

The phase 3 ASCENT-04/KEYNOTE-D19 trial evaluated patient-reported outcomes comparing sacituzumab govitecan plus pembrolizumab with chemotherapy plus pembrolizumab in previously untreated PD-L1–positive metastatic TNBC, offering insights into quality of life and symptom management. Read More ›

Low-Dose Pembrolizumab With Anthracycline and Taxane in Triple-Negative Breast Cancer: Results From a Randomized Controlled Trial

This trial evaluated the addition of low-dose pembrolizumab to neoadjuvant anthracycline and taxane regimens, revealing potential synergy in triple-negative breast cancer. Read More ›

Novel MUC1-C ADC Demonstrates Potent Antitumor Activity in Triple-Negative Breast Cancer

Real-World Insights Into Characteristics, Treatments, and Outcomes of HR-Positive/HER2-Negative EBC Patients Eligible for NATALEE and monarchE in Helsinki and Uusimaa Hospital District, Finland

This study highlights the remarkable antitumor potency of a novel MUC1-C ADC, offering a promising therapeutic option for patients with triple-negative breast cancer. Read More ›

Patient-Reported Outcomes of Camizestrant + CDK4/6 Inhibitors for ESR1 Mutations in HR-Positive/HER2-Negative Advanced Breast Cancer: Findings From SERENA-6

Real-world data from Finland highlight the persistent risk of recurrence in hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC) patients meeting NATALEE and monarchE criteria, underscoring the need for improved treatment strategies beyond standard care. Read More ›

Comprehensive Nursing Approaches for Oral Mucositis in TROP2 ADC Treatment: Early Intervention and Patient Support

The SERENA-6 trial evaluates patient-reported outcomes for camizestrant combined with cyclin-dependent kinase (CDK)4/6 inhibitors in hormone receptor (HR)-positive/HER2-negative advanced breast cancer patients with emergent ESR1 mutations during first-line endocrine therapy. Read More ›